OAK

Levan-stabilized Prussian blue nanoparticles targeting the CD44 receptor for the effective treatment of acute kidney injury

Metadata Downloads
Author(s)
Oh, Hyeryeon; Jung, Junyoung; Son, Panmo; Lee, Yeseo; Choi, Won Il; Tae, Giyoong
Type
Article
Citation
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, v.338, no.Part 2
Issued Date
2026-01
Abstract
Acute kidney injury (AKI) is a prevalent disease characterized by sudden loss of renal function. Nanozymes have emerged as promising therapeutic candidates because of their intrinsic reactive oxygen species (ROS)-scavenging capabilities and anti-inflammatory efficacy. However, their clinical translation has been hindered by limited bioavailability and lack of targeted tissue specificity. In this study, ROS-scavenging Prussian blue nanozymes were stabilized with levan polysaccharide (L-PB) to improve their colloidal stability, biocompatibility, and inflammation site-targeting ability. The resulting L-PB exhibited a stable hydrodynamic diameter of similar to 100 nm under physiological conditions for up to 2 weeks. In vitro assays confirmed the biocompatibility, effective ROS-scavenging activity, and significantly higher cellular internalization of L-PB than that of Prussian blue stabilized with bovine serum albumin (B-PB). In a glycerol-induced murine model of AKI, L-PB demonstrated selective accumulation in CD44 receptor-overexpressing injured kidneys and exhibited excellent therapeutic effects by mitigating oxidative stress and inflammation, with minimal systemic toxicity compared with B-PB. These findings indicate that L-PB, with CD44 active targeting, has potential as a novel targeted AKI therapeutic, enabling efficient treatment of various inflammation-related diseases.
Publisher
ELSEVIER
ISSN
0141-8130
DOI
10.1016/j.ijbiomac.2025.149767
URI
https://scholar.gist.ac.kr/handle/local/33508
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.